Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 27th March 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 12, 2018
Previous Article Next Article

A β-glucuronidase-responsive albumin-binding prodrug programmed for the double release of monomethyl auristatin E

Author affiliations

Abstract

We report on the synthesis, in vitro and in vivo biological evaluations of a dimeric β-glucuronidase-responsive albumin-binding prodrug designed for the double release of MMAE upon a single enzymatic activation step. This prodrug produced a significant antitumour activity in mice bearing subcutaneous LS174T colorectal adenocarcinoma xenografts without inducing side effects.

Graphical abstract: A β-glucuronidase-responsive albumin-binding prodrug programmed for the double release of monomethyl auristatin E

Back to tab navigation

Supplementary files

Publication details

The article was received on 14 Sep 2018, accepted on 25 Oct 2018 and first published on 26 Oct 2018


Article type: Research Article
DOI: 10.1039/C8MD00466H
Citation: Med. Chem. Commun., 2018,9, 2068-2071

  •   Request permissions

    A β-glucuronidase-responsive albumin-binding prodrug programmed for the double release of monomethyl auristatin E

    B. Renoux, L. Fangous, C. Hötten, E. Péraudeau, B. Eddhif, P. Poinot, J. Clarhaut and S. Papot, Med. Chem. Commun., 2018, 9, 2068
    DOI: 10.1039/C8MD00466H

Search articles by author

Spotlight

Advertisements